207 related articles for article (PubMed ID: 9566670)
1. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.
Pearce G; Ryan PF; Delmas PD; Tabensky DA; Seeman E
Br J Rheumatol; 1998 Mar; 37(3):292-9. PubMed ID: 9566670
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroid-induced bone loss in men.
Pearce G; Tabensky DA; Delmas PD; Baker HW; Seeman E
J Clin Endocrinol Metab; 1998 Mar; 83(3):801-6. PubMed ID: 9506731
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
4. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids.
Hanania NA; Chapman KR; Sturtridge WC; Szalai JP; Kesten S
J Allergy Clin Immunol; 1995 Nov; 96(5 Pt 1):571-9. PubMed ID: 7499672
[TBL] [Abstract][Full Text] [Related]
5. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
6. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
[TBL] [Abstract][Full Text] [Related]
7. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
9. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
Koetz KR; Ventz M; Diederich S; Quinkler M
J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.
Krogsgaard MR; Thamsborg G; Lund B
Ann Rheum Dis; 1996 Feb; 55(2):143-6. PubMed ID: 8712867
[TBL] [Abstract][Full Text] [Related]
13. [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort].
Krogsgaard MR; Thamsborg G; Lund B
Ugeskr Laeger; 1997 Jul; 159(30):4641-4. PubMed ID: 9245040
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
15. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis.
Ho YV; Briganti EM; Duan Y; Buchanan R; Hall S; Seeman E
Osteoporos Int; 1999; 9(2):134-8. PubMed ID: 10367040
[TBL] [Abstract][Full Text] [Related]
17. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
18. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.
Young NR; Baker HW; Liu G; Seeman E
J Clin Endocrinol Metab; 1993 Oct; 77(4):1028-32. PubMed ID: 8408450
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Nieminen M
Osteoporos Int; 1999; 10(2):128-36. PubMed ID: 10501793
[TBL] [Abstract][Full Text] [Related]
20. No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids.
Haugeberg G; Myklebust G; Dovland H; Mikkelsen B; Gran JT
Scand J Rheumatol; 2000; 29(3):163-9. PubMed ID: 10898068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
